Hemmel Amrania PhD is CEO of Digistain – a Harvard financed technology company spun out of Imperial College. Previously as a clinical scientist, Hemmel patented a novel technology to eliminate subjective bias in cancer diagnosis and improve patient outcome. For this work he received the President’s Award for Outstanding Research, the Royal Society Innovation Prize and the Cancer Research Pioneer Award.